Your browser is no longer supported. Please, upgrade your browser.
FIXX [NASD]
Homology Medicines, Inc.
Index- P/E- EPS (ttm)-2.81 Insider Own0.20% Shs Outstand48.05M Perf Week-9.76%
Market Cap379.85M Forward P/E- EPS next Y-2.63 Insider Trans-94.58% Shs Float37.84M Perf Month-35.94%
Income-128.70M PEG- EPS next Q-0.67 Inst Own64.90% Short Float5.71% Perf Quarter-50.00%
Sales2.70M P/S140.69 EPS this Y-13.60% Inst Trans-8.74% Short Ratio3.66 Perf Half Y-39.87%
Book/sh4.08 P/B1.59 EPS next Y3.00% ROA-49.50% Target Price- Perf Year-51.79%
Cash/sh3.70 P/C1.75 EPS next 5Y-9.40% ROE-65.40% 52W Range6.41 - 17.34 Perf YTD-42.69%
Dividend- P/FCF- EPS past 5Y- ROI-66.50% 52W High-63.38% Beta-
Dividend %- Quick Ratio9.70 Sales past 5Y- Gross Margin- 52W Low-0.94% ATR0.51
Employees205 Current Ratio9.70 Sales Q/Q66.70% Oper. Margin- RSI (14)21.50 Volatility6.15% 5.68%
OptionableYes Debt/Eq0.00 EPS Q/Q-12.80% Profit Margin- Rel Volume1.55 Prev Close6.47
ShortableYes LT Debt/Eq0.00 EarningsMar 11 AMC Payout- Avg Volume590.88K Price6.35
Recom1.60 SMA20-25.10% SMA50-38.24% SMA200-44.17% Volume915,189 Change-1.85%
Mar-02-21Initiated Stifel Hold $14
Dec-14-20Resumed H.C. Wainwright Buy $30
Aug-11-20Reiterated H.C. Wainwright Buy $37 → $30
Jun-25-20Resumed BofA/Merrill Buy $30
May-13-20Initiated RBC Capital Mkts Outperform $30
Mar-16-20Upgrade Oppenheimer Perform → Outperform $32
Feb-24-20Initiated Chardan Capital Markets Buy $34
Nov-01-19Initiated Oppenheimer Perform
Sep-10-19Initiated Robert W. Baird Outperform
Apr-12-19Initiated Evercore ISI Outperform
Feb-20-19Initiated H.C. Wainwright Buy $36
Jan-07-19Initiated Canaccord Genuity Buy $37
Sep-07-18Initiated B. Riley FBR Neutral $18.50
Apr-20-21 03:28AM  
Apr-14-21 08:30AM  
Apr-12-21 08:30AM  
Apr-07-21 12:15PM  
08:52AM  
Apr-06-21 04:19PM  
Mar-22-21 08:00AM  
Mar-11-21 07:05PM  
04:10PM  
Mar-04-21 12:30PM  
Mar-01-21 09:51AM  
07:30AM  
Feb-25-21 08:00AM  
Feb-19-21 02:30AM  
Feb-08-21 02:50PM  
Jan-06-21 08:00AM  
Dec-14-20 01:36PM  
Dec-11-20 07:05PM  
02:15PM  
Nov-25-20 10:36AM  
Nov-10-20 03:05PM  
Nov-09-20 07:00PM  
05:35PM  
04:05PM  
08:00AM  
Nov-08-20 09:56AM  
Nov-06-20 11:40AM  
Nov-05-20 09:15AM  
Nov-03-20 12:30PM  
Oct-29-20 06:50PM  
Oct-28-20 07:45PM  
Oct-27-20 06:13PM  
Oct-26-20 09:32PM  
05:37PM  
Oct-23-20 10:00PM  
02:25PM  
Oct-22-20 04:35PM  
08:30AM  
Oct-21-20 07:56PM  
12:26PM  
Oct-20-20 07:04PM  
Oct-19-20 03:35PM  
Oct-16-20 04:53PM  
Oct-15-20 01:33PM  
01:30PM  
12:00PM  
11:53AM  
11:30AM  
Oct-14-20 06:23PM  
05:28PM  
Oct-13-20 08:20PM  
04:30PM  
03:12PM  
02:55PM  
01:49PM  
10:55AM  
Oct-12-20 06:10PM  
05:00PM  
Oct-09-20 10:13PM  
04:15PM  
Oct-08-20 09:44PM  
Sep-18-20 09:00AM  
Aug-10-20 05:35PM  
04:05PM  
12:39PM  
12:38PM  
Aug-06-20 12:30PM  
Jul-27-20 11:42PM  
Jul-21-20 08:00AM  
Jul-08-20 08:49AM  
Jun-29-20 10:49AM  
Jun-27-20 02:58PM  
May-26-20 02:11PM  
May-19-20 04:08PM  
May-12-20 08:00AM  
May-10-20 09:45AM  
May-07-20 04:05PM  
Apr-29-20 08:00AM  
Apr-03-20 09:44AM  
Mar-16-20 09:00AM  
Mar-14-20 09:14AM  
Mar-12-20 05:45PM  
04:10PM  
Mar-11-20 09:22AM  
Mar-03-20 12:30PM  
Feb-20-20 09:00AM  
Feb-17-20 10:06AM  
Feb-13-20 09:00AM  
Jan-31-20 11:52AM  
Jan-14-20 08:33AM  
Jan-13-20 02:30PM  
Jan-10-20 02:20PM  
Jan-01-20 08:01AM  
Dec-24-19 10:49AM  
Dec-18-19 10:23AM  
07:23AM  
Dec-17-19 04:01PM  
Dec-16-19 09:00AM  
Dec-13-19 02:44PM  
Dec-03-19 08:30AM  
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase I/II pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II. Homology Medicines, Inc. was incorporated in 2015 and is based in Bedford, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kelly Timothy PSee Remarks.Mar 01Option Exercise4.764,00019,0526,232Mar 03 04:05 PM
Smith W BradfordCFO & TreasurerFeb 08Option Exercise0.6413,5008,64013,500Feb 09 04:22 PM
Smith W BradfordCFO & TreasurerFeb 08Sale14.2513,500192,4250Feb 09 04:22 PM
Kelly Timothy PSee RemarksFeb 02Option Exercise6.635003,316500Feb 05 06:31 AM
Kelly Timothy PSee RemarksFeb 02Sale13.005006,5000Feb 05 06:31 AM
Kelly Timothy PSee RemarksFeb 01Option Exercise4.764,00019,0524,000Feb 03 04:05 PM
Kelly Timothy PSee RemarksFeb 01Sale12.374,00049,4600Feb 03 04:05 PM
Kelly Timothy PSee RemarksJan 12Option Exercise6.635003,316500Jan 14 04:05 PM
Kelly Timothy PSee RemarksJan 12Sale13.005006,5000Jan 14 04:05 PM
Seymour AlbertChief Scientific OfficerJan 07Sale12.055,10361,469129,017Jan 08 04:05 PM
Seymour AlbertChief Scientific OfficerJan 06Sale12.069,897119,395134,120Jan 08 04:05 PM
Seymour AlbertChief Scientific OfficerJan 05Sale11.4410,000114,422144,017Jan 07 04:05 PM
Kelly Timothy PSee RemarksJan 04Option Exercise4.764,00019,0524,000Jan 06 04:05 PM
Kelly Timothy PSee RemarksJan 04Sale11.504,00045,9830Jan 06 04:05 PM
PARMAR KUSHDirectorDec 22Sale12.82500,0006,410,000181,435Dec 28 09:37 PM
5AM Ventures IV, L.P.10% OwnerDec 22Sale12.82500,0006,410,000181,435Dec 28 09:35 PM
PARMAR KUSHDirectorDec 14Sale12.25500,0006,125,915201,435Dec 16 07:25 PM
5AM Ventures IV, L.P.10% OwnerDec 14Sale12.25500,0006,125,915201,435Dec 16 07:15 PM